DaVita

DVA · NYSE

$175.35−$11.65 (−6.23%)TodayMarket closed ·
Prev close $187.00

Latest news

  • Press releasePRNewswire

    DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice

  • NewsPiero Cingari

    Health Care Stocks Hit Record Highs, GM Drops Nearly 8%: Stock Market Today

  • Press releasePRNewswire

    DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call

  • Press releasePRNewswire

    DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

  • Press releasePRNewswire

    DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early

  • NewsRishabh Mishra

    Michael Burry Warns Anthropic’s Valuation Could Buy 78 Profitable S&P 500 Companies: ‘Fun Game in Times Like These’

  • News

    10 Health Care Stocks Whale Activity In Today’s Session

  • NewsChris Katje

    Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You

  • NewsVandana Singh

    DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack

  • NewsRadhika Anilkumar Nadig

    Berkshire Hathaway Cut Capital One Stake by 58% in Q2 — Billionaire Dan Loeb Is Doing the Exact Opposite

  • Press releasePRNewswire

    Alebund Pharmaceuticals Announces 2026 Interim Results

  • Press releasePRNewswire

    DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease

  • NewsPiero Cingari

    The Economy Lost Jobs, Wall Street Threw a Party: What Moved Markets This Week

  • NewsPiero Cingari

    Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today

  • NewsAvi Kapoor

    SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

  • News

    DaVita Q2 Adj. EPS $4.02 Beats $3.88 Estimate, Sales $3.554B Beat $3.496B Estimate

  • Press releasePRNewswire

    DaVita Inc. 2nd Quarter 2026 Results

  • Press releasePRNewswire

    DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call

  • News

    8 Health Care Stocks Whale Activity In Today’s Session

  • Press releasePRNewswire

    DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals

  • NewsPiero Cingari

    S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today

  • Press releasePRNewswire

    DaVita Inc. 1st Quarter 2026 Results

  • Press releasePRNewswire

    Honeywell Announces Board of Directors for Honeywell Aerospace

  • Press releasePRNewswire

    DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

  • Press releasePRNewswire

    DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

  • Press releasePRNewswire

    Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

  • Press releaseGlobe Newswire

    R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

  • Press releasePRNewswire

    DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference

  • NewsVandana Singh

    DaVita Stock Rallies On Profit Beat, Confident 2026 View

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • NewsAvi Kapoor

    Silver Surges Over 15%; Pfizer Earnings Top Views

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    DaVita Inc. 4th Quarter 2025 Results

  • Press releaseBusiness Wire

    Elara Caring Secures New Strategic Investment from Ares and DaVita

  • Press releaseBusiness Wire

    Tolion Health AI Appoints Global Health & AI Leader Gregory J. Moore, MD, PhD, to Board of Directors

  • Press releasePRNewswire

    DaVita Inc. 3rd Quarter 2025 Results

  • Press releasePRNewswire

    DaVita Inc. 2nd Quarter 2025 Results

  • NewsSnigdha Gairola

    Warren Buffett's Berkshire Hathaway Offloads $230 Million In DaVita Stock Ahead Of Q2 Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.